Sequana Medical

• Initial public offering on Euronext Brussels of 3,235,294 primary shares at a price of €8.50 per share
• Gross proceeds will be used to support the execution of the Company’s strategy, in particular the North American pivotal study on the alfapump^® for the treatment of liver recurrent and refractory ascites, the European commercial roll-out, and other clinical development programmes
• Kempen extensively marketed the transaction towards specialist and generalist institutional investors during investor education (PDIE) and bookbuilding
• In addition, Van Lanschot Private banking marketed the transaction to their clients in Belgium
• The orderbook has been built with strong local support from high-quality long-term institutional investors as well as a mix of long-term, specialist and generalist investors across Europe; the transaction furthermore attracted strong support from Belgian retail investors which, in line with Belgian law, were allocated c. 10% of the IPO
• Trading of Sequana Medical's shares on the regulated market of Euronext Brussels under the symbol "SEQUA" commenced on 11 February 2019
• Sequana Medical’s IPO marks the second European Life Sciences initial public offering in 2019 and the third successful Kempen Life Sciences ECM transaction this year

Sequana Medical is a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical's lead product alfapump^® is a fully implantable, programmable, wirelessly-charged, battery-powered system that is CE-marked for the management of i) refractory ascites (chronic fluid build-up in the abdomen) due to liver cirrhosis and ii) malignant ascites (with a life expectancy of six months or less). The company recently received Breakthrough Device designation from the FDA for its alfapump^® for the treatment of liver recurrent or refractory ascites. The number of patients with liver refractory ascites is forecasted to increase dramatically due to the growing prevalence of NASH (Non-alcoholic Steatohepatitis). Sequana Medical is developing the alfapump^® DSR, built upon the proven alfapump^® platform, to deliver a convenient and fully implanted system for Direct Sodium Removal ("DSR") therapy, a novel and proprietary approach for the management of volume overload in heart failure. A first in human study for DSR therapy is ongoing. Sequana Medical is headquartered in Ghent, Belgium.